Forced expiratory volume in 1 second (FEV1) measures how much air you can forcefully exhale in one second. A low FEV1 suggests a breathing obstruction caused by conditions like chronic obstructive ...

Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE ...

Asthma metabolomics uncovered biologically distinct disease subtypes in clinically stable patients. Learn more about the ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Whether it’s a short flight of stairs or anxiety, breathlessness happens. But if it lingers or feels out of proportion, it ...

April 2026 Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and olderApproval based on KALOS and LOGOS Phase III trials demonstrating statistically ...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...

Nebuliser use in COPD is highest in severe cases, reflecting worsening symptoms, frequent exacerbations, and the need for improved treatment strategies.

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...

Regeneron Pharmaceuticals, Inc. ( REGN) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDT ...

Audio Gap] chatting with Kymera Therapeutics. Up here on stage, we've got a couple of members from the management team. We've got Bruce Jacobs, who's, of course, is Chief Financial Officer; as well as ...